Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal trends in viral SetPoint and peak CD4 cell count soon after HIV-1 seroconversion.

AIDS (London, England)·2026
Same author

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV.

AIDS (London, England)·2026
Same author

Psychometric properties of the Flourishing scale in Greek adult population.

BMC psychology·2026
Same author

Remdesivir: Real-World Effectiveness and Safety in Individuals Hospitalized for Non-COVID Reasons and Non-Hospitalized High-Risk Patients During the Omicron Era in Greece.

Microorganisms·2026
Same author

Design and development of an automated surveillance system for outbreak detection and individual risk assessment for HIV and viral hepatitis B and C among people who use drugs: The Hippocrates project.

The International journal on drug policy·2026
Same author

Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.

Circulation·2026
Same journal

A joint model for a longitudinal outcome and a progressive multistate model under a mixed observation scheme.

Statistical methods in medical research·2026
Same journal

Efficient semi-supervised estimation of optimal individualized treatment regimes with survival outcome.

Statistical methods in medical research·2026
Same journal

Asymptotic online FWER control for dependent test statistics.

Statistical methods in medical research·2026
Same journal

Regression analysis of misclassified current status data with potentially unknown test accuracy.

Statistical methods in medical research·2026
Same journal

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026
Same journal

Inference about the ratio of age-standardized rates between two overlapping populations.

Statistical methods in medical research·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Practical methods for competing risks data: a review.

Giorgos Bakoyannis1, Giota Touloumi

  • 1Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece.

Statistical Methods in Medical Research
|January 11, 2011
PubMed
Summary
This summary is machine-generated.

This study reviews statistical methods for competing risks data, common in medical research. The Fine and Gray model is robust to administrative censoring assumptions, crucial for HIV studies.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 5, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

  • Biostatistics
  • Epidemiology
  • Medical Research

Background:

  • Competing risks data are prevalent in medical research, involving multiple, mutually exclusive events.
  • The framework extends to non-mutually exclusive events where the first occurrence is of primary interest, such as in HIV treatment studies.

Purpose of the Study:

  • To introduce competing risks data and critically review statistical estimation and modeling methods.
  • To discuss the Fine and Gray model for subdistribution hazard and its robustness to administrative censoring assumptions.

Main Methods:

  • Review of statistical methods for competing risks data.
  • Discussion of the Fine and Gray model for subdistribution hazard.
  • Simulation study to assess the impact of administrative censoring assumption on inference.

Main Results:

  • The Fine and Gray model is widely used and can be fitted using standard software under administrative censoring.
  • Simulation results indicate that the assumption of administrative censoring has a limited effect on parameter estimates and confidence interval coverage in various scenarios.

Conclusions:

  • The Fine and Gray model provides a valuable tool for analyzing competing risks data in medical research.
  • The robustness of the model to administrative censoring assumptions enhances its applicability, particularly in HIV research like the CASCADE study.